###begin article-title 0
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMS2 </italic>
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 90 95 <span type="species:ncbi:4932">yeast</span>
Assessing pathogenicity of MLH1 variants by co-expression of human MLH1 and PMS2 genes in yeast
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 397 405 397 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 447 452 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 643 649 643 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 659 666 659 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 37 43 <span type="species:ncbi:9606">humans</span>
###xml 694 699 <span type="species:ncbi:9606">human</span>
###xml 717 722 <span type="species:ncbi:4932">yeast</span>
Loss of DNA mismatch repair (MMR) in humans, mainly due to mutations in the hMLH1 gene, is linked to hereditary nonpolyposis colorectal cancer (HNPCC). Because not all MLH1 alterations result in loss of MMR function, accurate characterization of variants and their classification in terms of their effect on MMR function is essential for reliable genetic testing and effective treatment. To date, in vivo assays for functional characterization of MLH1 mutations performed in various model systems have used episomal expression of the modified MMR genes. We describe here a novel approach to determine accurately the functional significance of hMLH1 mutations in vivo, based on co-expression of human MLH1 and PMS2 in yeast cells.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMS1 </italic>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
###xml 123 128 <span type="species:ncbi:4932">yeast</span>
Yeast MLH1 and PMS1 genes, whose protein products form the MutLalpha complex, were replaced by human orthologs directly on yeast chromosomes by homologous recombination, and the resulting MMR activity was tested.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 4 9 <span type="species:ncbi:4932">yeast</span>
###xml 193 198 <span type="species:ncbi:4932">yeast</span>
The yeast strain co-expressing hMLH1 and hPMS2 exhibited the same mutation rate as the wild-type. Eight cancer-related MLH1 variants were introduced, using the same approach, into the prepared yeast model, and their effect on MMR function was determined. Five variants (A92P, S93G, I219V, K618R and K618T) were classified as non-pathogenic, whereas variants T117M, Y646C and R659Q were characterized as pathogenic.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 23 28 <span type="species:ncbi:4932">yeast</span>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
Results of our in vivo yeast-based approach correlate well with clinical data in five out of seven hMLH1 variants and the described model was thus shown to be useful for functional characterization of MLH1 variants in cancer patients found throughout the entire coding region of the gene.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 629 635 629 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 639 645 639 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH2 </italic>
###xml 646 647 646 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 786 787 786 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1126 1127 1126 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Mismatch repair (MMR) genes are genome-stability genes. Mutations in these genes cause defects in the MMR pathway that can lead to carcinogenesis, as a result of accumulation of non-repaired post-replicational mis-incorporations in cancer contributing genes. Inherited germline mutations of MMR genes cause a predisposition to cancer, which can develop at an early age, as the next somatic mutation needs to affect only one, wild-type allele of a gene [1,2]. It has been established that many families with hereditary non-polyposis colorectal cancer (HNPCC) harbour potentially pathogenic mutations in MMR genes, particularly in hMLH1 and hMSH2 [3]. The disease manifests with high mortality rate if not detected and treated early, therefore presymptomatic genetic testing is required [4]. However, the functional effects of MMR mutations need to be characterized first. This is essential, not only for effective diagnosis of cancer predisposition, but also for choosing the appropriate chemotherapy, since it is known that MMR mutations can cause resistance to chemotherapeutic agents by insufficient induction of apoptosis [5].
###end p 11
###begin p 12
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH2 </italic>
###xml 220 229 220 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 233 241 233 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 350 359 350 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 632 633 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 634 635 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 689 694 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 853 854 853 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 857 865 857 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo </italic>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1257 1259 1257 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1260 1262 1260 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1265 1270 1265 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 1458 1460 1458 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
###xml 607 612 <span type="species:ncbi:4932">yeast</span>
###xml 909 914 <span type="species:ncbi:4932">yeast</span>
###xml 972 977 <span type="species:ncbi:9606">human</span>
###xml 1051 1056 <span type="species:ncbi:4932">yeast</span>
###xml 1084 1089 <span type="species:ncbi:4932">yeast</span>
###xml 1164 1172 <span type="species:ncbi:9606">patients</span>
###xml 1234 1239 <span type="species:ncbi:9606">human</span>
###xml 1244 1249 <span type="species:ncbi:4932">yeast</span>
###xml 1305 1310 <span type="species:ncbi:9606">human</span>
There are over 450 germline allelic variants of hMLH1 and hMSH2 genes known to date and more are being found, but the functional relevance of each is very difficult to establish on clinical samples alone. Therefore many in vitro and in vivo assays have been developed for MMR gene mutation analysis, using various molecular genetics tools [6-16]. An in vitro functional analysis - involving Western immunoblotting - of four hMLH1 mutations found in HNPCC patients was described by Belvederesi et al. [6]. Several other strategies have been based on analysing the interaction between MMR variants, using the yeast two-hybrid system [7,8]. One recent study described the characterization of MLH1 variants in terms of multiple functional properties (e.g. protein expression/stability, nuclear localization, protein-protein interaction and MMR efficiency) [9]. In vivo assays have been performed in bacterial and yeast model systems, all of them using expression vectors with human MMR gene variants [10-13]. An alternative, commonly reported approach in yeast is the use of vectors with yeast MMR orthologs harbouring a mutation corresponding to those found in HNPCC patients, but the method is limited by the degree of homology between human and yeast genes [14,15]. MLH1 variants were also introduced into human cell lines to analyze their effects on apoptosis, proliferation, and regulation of mRNA expression, as well as expression of interacting proteins [16].
###end p 12
###begin p 13
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 471 479 471 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 532 538 532 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 600 606 600 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2 </italic>
###xml 610 616 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 1034 1042 1030 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1171 1179 1167 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1240 1248 1236 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1328 1334 1324 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 697 702 <span type="species:ncbi:4932">yeast</span>
###xml 729 734 <span type="species:ncbi:4932">yeast</span>
###xml 848 853 <span type="species:ncbi:9606">human</span>
###xml 890 895 <span type="species:ncbi:4932">yeast</span>
###xml 923 928 <span type="species:ncbi:4932">yeast</span>
###xml 1248 1253 <span type="species:ncbi:4932">yeast</span>
Although these studies have provided valuable clues to a better understanding of MLH1 variants, it is difficult to establish and compare their clinical relevance since a variety of strategies have been used. We believe that for reliable interpretation of functional effects of MLH1 gene mutations and their classification, all MLH1 mutations extending within the whole gene coding region should be analyzed using the same approach. In this study we are proposing a novel in vivo approach to determine the functional significance of hMLH1 mutations throughout the whole coding region of the gene. The hPMS2 and hMLH1 genes, whose proteins form the hMutLalpha complex, were each introduced into the yeast chromosome, replacing the yeast orthologs. Direct chromosomal integration enabled just one copy of a target gene to be introduced per cell. Both human orthologs were under control of the yeast promoter, and the original yeast genetic background was preserved. The functionality of mismatch repair was examined using a quantitative in vivo DNA MMR assay. To assess the functionality of the novel test system, nine different MLH1 amino acid replacements were introduced in vivo and evaluated for their pathogenicity. Results show that our in vivo yeast-based approach can help assess the pathogenic potential of cancer-related hMLH1 variants.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast strain and vectors
###end title 15
###begin p 16
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 688 690 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 713 715 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1065 1067 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1255 1257 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 4 9 <span type="species:ncbi:4932">yeast</span>
###xml 10 34 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 190 195 <span type="species:ncbi:4932">yeast</span>
###xml 277 282 <span type="species:ncbi:4932">yeast</span>
###xml 474 481 <span type="species:ncbi:562">E. coli</span>
###xml 736 741 <span type="species:ncbi:4932">yeast</span>
###xml 1084 1089 <span type="species:ncbi:4932">yeast</span>
The yeast Saccharomyces cerevisiae haploid strain used was W303-1A/RE966 (MATa ade2 can1-100 his3-11,15 leu2-3, 112 trp1-1 ura3-1) [17]. Cells were maintained in standard rich medium (YPD) [yeast extract/peptone/dextrose] and in selective synthetic medium (SD) [YNB: 0,67% w/v yeast nitrogen base, 2% w/v dextrose] supplemented with amino acids, depending on the auxotrophic requirements, and grown at 30degreesC. Media were solidified by addition of 2% w/v bacto-agar. The E. coli DH5alpha strain was used as bacterial host for plasmid propagation. Plasmid pCORE with KlURA3-kanMX4 counter-selectable reporter marker cassette (CORE) and plasmid pSH91 were provided by Francesca Storici [18] and Thomas D. Petes [19], respectively. The yeast expression vector pSH91 used for in vivo MMR assay contains an in-frame (GT)16.5 tract in the URA3 coding region. hMLH1 [GeneBank: ] and hPMS2 [GeneBank: ] cDNAs were obtained from pCMV-SPORT6 vector (ATCC, MGC-5172) and pSG-PMS2-wt, respectively. The latter plasmid was provided by Bert Vogelstein and Kenneth W. Kinzler [20]. Expression of yeast URA3 gene in pSH91 is under LEU2 gene promoter, so all test strains were transformed with Yep181 vector expressing LEU2 gene for restoration of leucine prototrophy [21].
###end p 16
###begin title 17
###xml 26 31 <span type="species:ncbi:4932">yeast</span>
Construction of humanized yeast strains
###end title 17
###begin p 18
###xml 4 20 3 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">delitto perfetto</italic>
###xml 113 115 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 118 135 116 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Delitto Perfetto </italic>
###xml 162 170 160 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 265 277 263 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S cerevisiae</italic>
###xml 499 500 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 66 71 <span type="species:ncbi:4932">yeast</span>
###xml 199 204 <span type="species:ncbi:4932">yeast</span>
###xml 545 550 <span type="species:ncbi:4932">yeast</span>
A >>delitto perfetto<< method was used for constructing humanized yeast strains, as described by Storici et al. [18]. Delitto Perfetto is a two step approach for in vivo site-directed mutagenesis in yeast, using highly proficient homologous recombination system of S cerevisiae. The first step involves integration of a counterselectable (CORE) cassette in the region of interest. Subsequently, the CORE cassette is replaced with DNA fragment containing the mutation or the gene of interest (Figure 1). The CORE cassette allows the selection of yeast cells that receive the cassette during the first step, as well as selection of cells that lose the cassette in the second step of the process.
###end p 18
###begin p 19
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Constructing humanized yeast strains with delitto perfetto system</bold>
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yMMR</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMMR</italic>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line</italic>
###xml 483 489 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 518 524 518 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 528 534 528 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2 </italic>
###xml 586 591 586 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1</italic>
###xml 627 646 627 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black vertical line</italic>
###xml 745 765 745 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow vertical line</italic>
###xml 787 803 787 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">delitto perfetto</italic>
###xml 838 847 838 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">grey area</italic>
###xml 23 28 <span type="species:ncbi:4932">yeast</span>
###xml 80 85 <span type="species:ncbi:4932">yeast</span>
###xml 137 142 <span type="species:ncbi:9606">human</span>
###xml 206 211 <span type="species:ncbi:4932">yeast</span>
###xml 256 261 <span type="species:ncbi:4932">yeast</span>
###xml 285 290 <span type="species:ncbi:4932">yeast</span>
###xml 393 398 <span type="species:ncbi:4932">yeast</span>
###xml 426 431 <span type="species:ncbi:9606">human</span>
Constructing humanized yeast strains with delitto perfetto system. A. Replacing yeast MMR (yMMR) genes (i.e. yMLH1 and yPMS1) with their human orthologs (hMMR). First, the CORE cassette was introduced into yeast chromosome (line) after the stop codon of a yeast MMR gene, enabling the yeast gene to be still active during the second step of the process. Next, together with CORE cassette, the yeast gene was replaced with its human ortholog. B. Introducing missense alterations into hMLH1 gene in strain co-expressing hMLH1 and hPMS2 genes. First, the CORE cassette was introduced into hMLH1, replacing nucleotide of interest (black vertical line). Next, the CORE cassette was replaced by DNA fragment harbouring a single-nucleotide alteration (yellow vertical line). Genetic technique, delitto perfetto, is based on recombination event (grey area) between two identical strand of DNA.
###end p 19
###begin p 20
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KlURA3 </italic>
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">kanMX4 </italic>
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yMLH1 </italic>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 559 563 559 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 563 567 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfx </italic>
###xml 666 668 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 888 894 885 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 927 932 924 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 1314 1318 1311 1313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 131 136 <span type="species:ncbi:4932">yeast</span>
###xml 348 353 <span type="species:ncbi:4932">yeast</span>
###xml 615 620 <span type="species:ncbi:4932">yeast</span>
###xml 671 676 <span type="species:ncbi:4932">Yeast</span>
###xml 908 913 <span type="species:ncbi:4932">yeast</span>
###xml 921 926 <span type="species:ncbi:9606">Human</span>
In this study, the counter-selectable reporter (CORE) cassette with KlURA3 and kanMX4 was amplified from pCORE and integrated into yeast chromosome XIII after the stop codon of the yMLH1 coding region (Figure 1A). 60- to 70-meric oligonucleotides (Sigma-Aldrich), consisting of 40- to 50-nucleotide flanking regions homologous with the appropriate yeast genomic target locus and a 20-nucleotide tract required for amplification from the vector were used for the amplification. DNA fragments were amplified by the polymerase chain reaction (PCR) using Platinum(R) Pfx DNA polymerase (Invitrogen) and introduced into yeast cells with the LiAc transformation protocol [22]. Yeast clones that integrated CORE cassette into their genome were selected on YPD plates containing 200 mug/mL of geneticin (G418; Sigma-Aldrich). The CORE cassette was then completely removed by introducing complete hMLH1 cDNA into the yeast cells. Human MLH1 cDNA was previously amplified from pCMV-SPORT6 vector using 60-meric oligonucleotides. After transformation, the resulting Ura-cells, which lost CORE cassette, were isolated from synthetic complete medium containing 1 mg/L 5-fluororotic acid monohydrate (5-FOA; Toronto Research Chemicals Inc.). Isolated clones (strain MV200) were identified by PCR, using Taq polymerase (Eppendorf(R) Master Mix), and the nucleotide sequences of the constructs were confirmed by DNA sequencing (Sequiserve).
###end p 20
###begin p 21
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yPMS1 </italic>
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2 </italic>
###xml 559 565 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 569 575 569 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2 </italic>
###xml 610 616 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yMLH1 </italic>
###xml 621 627 621 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 675 680 675 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2</italic>
###xml 204 209 <span type="species:ncbi:4932">yeast</span>
###xml 392 397 <span type="species:ncbi:4932">yeast</span>
###xml 452 457 <span type="species:ncbi:4932">yeast</span>
###xml 530 535 <span type="species:ncbi:4932">yeast</span>
To replace yPMS1 by hPMS2 directly on the chromosome (strain MV300), the CORE cassette was amplified with 60-meric oligonucleotides from pCORE and introduced after the stop codon of the yPMS1 gene in the yeast chromosome. The integrated CORE cassette, together with the yPMS1 gene, was then replaced by hPMS2 cDNA, previously amplified from vector pSG-PMS2-wt with oligonucleotides targeting yeast chromosome XIV. PCR products were introduced into the yeast cells and clones were isolated as described above. In order to obtain a yeast strain containing both hMLH1 and hPMS2 (strain MV400), the replacement of yMLH1 with hMLH1 was done in the strain MV300 already harbouring hPMS2.
###end p 21
###begin p 22
###xml 10 22 10 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mlh1::kanMX </italic>
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yMLH1 </italic>
###xml 108 114 108 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">kanMX </italic>
###xml 4 9 <span type="species:ncbi:4932">yeast</span>
The yeast mlh1::kanMX gene disruption was constructed by replacing the entire yMLH1 gene coding region with kanMX gene amplified from pFA6aKanMX4. Clones (strain MV100) were selected on YPD plates containing G418 and identified by PCR.
###end p 22
###begin p 23
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 313 322 313 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 431 436 <span type="species:ncbi:4932">yeast</span>
When constructing MLH1 single-nucleotide substitutions (Figure 1B), the CORE cassettes were amplified from pCORE with oligonucleotides targeting the human ortholog at the relevant codons. Integrative 3'-overlapping recombinant oligonucleotides harbouring the desired single-nucleotide substitutions were extended in vitro as described by Storici et al [18]. PCR products were again transformed into appropriate geneticin resistant yeast cells and clones were isolated as described above. All oligonucleotide sequences are available upon request.
###end p 23
###begin title 24
In vivo MMR assay and statistical analysis
###end title 24
###begin p 25
###xml 17 25 17 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">URA3 </italic>
###xml 367 372 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3 </italic>
###xml 412 417 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3 </italic>
###xml 493 498 493 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">URA3 </italic>
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LEU2 </italic>
###xml 162 167 <span type="species:ncbi:4932">yeast</span>
###xml 487 492 <span type="species:ncbi:4932">yeast</span>
The standardized in vivo MMR assay has been described in detail elsewhere [23]. The assay is based on stability of 33 bp GT tract, which is inserted in-frame the yeast URA3 gene in plasmid pSH91, as a measure of MMR efficiency. Instability of dinucleotide repeat is associated with DNA polymerase slipping during replication and alterations in tract length result in ura3 mutants, if not repaired by MMR. Mutant ura3 cells can be measured by their resistance to 5-FOA. Expression of the yeast URA3 gene in pSH91 is under LEU2 gene promoter, so all strains have to be leucine prototrophs.
###end p 25
###begin p 26
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1183 1185 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 82 87 <span type="species:ncbi:4932">yeast</span>
###xml 135 140 <span type="species:ncbi:4932">yeast</span>
In brief, plasmids pSH91 and Yep181 were first transformed [24] into the prepared yeast strains. At least 12 colonies of each analyzed yeast strain were picked from selective media plates (lacking tryptophan, leucine and uracil) and grown to saturation in SD supplemented with adenine and histidine to ensure that the starting cultures were homogeneous for URA3 cells with in-frame GT tracts. Cultures were diluted 1:1000 into SD supplemented with adenine, histidine and uracil, and grown to OD660 of 1. This allowed growth of all cells, including newly arising ura3 mutants. Each culture was then serially diluted and plated on SD plates supplemented with adenine, histidine and uracil, and the number of colonies was counted after a 3-day incubation to determine cell concentration. 100 muL aliquots of undiluted culture were plated on SD plates supplemented with adenine, histidine and uracil and containing 5-FOA. Colonies were counted after 3 days to calculate the concentration of ura3 mutants. Strains with increased instability of the GT tract, due to a disrupted MMR system, resulted in the ura3 mutant strain. Mutation rates were calculated using the method of the median [25]. For statistical analysis, Mann-Whitney tests were performed between all strains using GraphPad-InStat software. Differences in mutation rates were considered significant when P </= 0.05.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 39 44 <span type="species:ncbi:4932">yeast</span>
Characterization of human MMR genes in yeast
###end title 28
###begin p 29
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2 </italic>
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 285 293 285 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 334 339 334 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">16.5 </sub>
###xml 345 352 345 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 400 403 400 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">kan</italic>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
###xml 646 647 646 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 86 91 <span type="species:ncbi:4932">yeast</span>
###xml 185 190 <span type="species:ncbi:4932">yeast</span>
###xml 222 227 <span type="species:ncbi:9606">human</span>
###xml 441 446 <span type="species:ncbi:4932">yeast</span>
For functional analysis of HNPCC-related hMLH1 variants we prepared several humanized yeast strains with hPMS2 and different hMLH1 variants inserted into the genome and replacing their yeast orthologs. The function of the human MLH1 protein variants was determined with a standardized in vivo MMR assay measuring stability of the (GT)16.5 tract in vivo. A MV100 strain was constructed by integrating kanMX gene into the coding region of the yeast MLH1. By this intervention the ability of MMR to repair insertion/deletion loops on microsatellite GT tract was completely disrupted, with 79-fold greater mutation rate than in the wild-type (Figure 2).
###end p 29
###begin p 30
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The MMR efficiency in yeast strains harbouring endogenous and/or human MMR genes</bold>
###xml 226 229 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 264 266 264 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 283 285 283 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 302 304 302 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 22 27 <span type="species:ncbi:4932">yeast</span>
###xml 65 70 <span type="species:ncbi:9606">human</span>
The MMR efficiency in yeast strains harbouring endogenous and/or human MMR genes. Each datum is the mean, with a 95% confidence interval indicated, of three independent experiments. Mean mutation rates are: Wild-type 2.19 x 10-6 ; MV100 1.74 x 104; MV200 6.05 x 10-5; MV300 8.86 x 10-5; MV400 2.25 x 10-6. Genotypes of strains are boxed. All prepared strains originated from W303 background [17].
###end p 30
###begin p 31
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 199 204 199 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 661 666 661 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 789 794 789 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 958 959 958 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1013 1018 1013 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMS1 </italic>
###xml 1042 1047 1042 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMS2 </italic>
###xml 1081 1087 1081 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 1260 1261 1260 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1328 1330 1328 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1376 1382 1376 1382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2 </italic>
###xml 31 36 <span type="species:ncbi:4932">yeast</span>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 117 122 <span type="species:ncbi:4932">yeast</span>
###xml 193 198 <span type="species:ncbi:4932">yeast</span>
###xml 232 237 <span type="species:ncbi:9606">human</span>
###xml 296 301 <span type="species:ncbi:4932">yeast</span>
###xml 655 660 <span type="species:ncbi:4932">yeast</span>
###xml 716 721 <span type="species:ncbi:4932">yeast</span>
###xml 783 788 <span type="species:ncbi:9606">human</span>
###xml 826 831 <span type="species:ncbi:9606">human</span>
###xml 866 871 <span type="species:ncbi:4932">yeast</span>
###xml 1007 1012 <span type="species:ncbi:4932">yeast</span>
###xml 1036 1041 <span type="species:ncbi:9606">human</span>
###xml 1110 1115 <span type="species:ncbi:9606">human</span>
###xml 1240 1245 <span type="species:ncbi:4932">yeast</span>
For in vivo replacement of the yeast MLH1 gene by its human ortholog, we first integrated the CORE cassette into the yeast MLH1 gene. Experiments replacing the CORE cassette at codon 73 of the yeast MLH1 coding region with complete human MLH1 cDNA failed (data not shown). It was shown before in yeast, that MLH1 can play a role in regulating mitotic recombination [26] and we believe that its disruption, in our case by the integrated CORE cassette, could have a negative impact on recombination events needed for successful replacement of the cassette. For this reason we engineered an alternative gene fusion by integrating the CORE cassette after the yeast MLH1 stop codon, thus maintaining the integrity of the yeast gene. Replacement of this fusion construct with the complete human MLH1 cDNA was now feasible. However, human MLH1 alone did not complement the yeast ortholog and exhibited a 28-fold increase in mutation rate over the wild-type (Figure 2). Using the same strategy we then replaced the yeast PMS1 with the complete human PMS2 cDNA in the strain harbouring the hMLH1 gene. Co-expression of human MLH1 and PMS2 (strain MV400) indicated that the exogenous hMLH1-hPMS2 complex was able to fully restore the MMR function in yeast cells (Figure 2). Mutation rate was the same as observed in the wild-type strain (P = 0.89). However, the MV300 strain expressing hPMS2 alone exhibited a 40-fold higher mutation rate than that in the wild-type parental strain.
###end p 31
###begin title 32
The described system is operational for functional characterization of hMLH1 alterations
###end title 32
###begin p 33
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 841 849 841 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 881 887 881 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 891 897 891 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2 </italic>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
Our approach was shown to be operational for functional analysis of hMLH1 mutations by assessing eight different hMLH1 missense mutations found in cancer patients. Two variants (T117M and I219V) have already been evaluated by several different functional assays (Table 1). Because of the consistency of data obtained from the assays and their correlation with clinical reports, these variants were included as experimental controls in our study. We further analyzed the impact on phenotype of six missense mutations (A92P, S93G, K618R, K618T, Y646C and R659Q). An additional, non-cancer-associated frameshift mutation (1955 del 1 bp), which determines an early stop codon at position 660, was used to evaluate the impact of a clear loss-of-function mutation. All nucleotide rearrangements resulting in relevant codon changes were introduced in vivo into strain MV400 co-expressing hMLH1 and hPMS2 genes.
###end p 33
###begin p 34
Comparison of published functional and clinical data on hMLH1 variants
###end p 34
###begin p 35
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 90 156 88 154 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Each symbol refers to the assay referenced in section: Assay type.</underline>
aThe outcome of each assay is given: +, pathogenic; -, non-pathogenic; +/-, inconclusive. Each symbol refers to the assay referenced in section: Assay type.
###end p 35
###begin p 36
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bMicrosatellite instability.
###end p 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cImmunohistochemical staining of MLH1: POS, positive; NEG, negative.
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
dPatients' age at cancer onset.
###end p 38
###begin p 39
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
eThe variant was also found in patients carrying a second MMR alteration. Those patients were excluded from the Table.
###end p 39
###begin p 40
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
fImmunohistochemical staining of PMS2. In this case MLH1 staining was positive.
###end p 40
###begin p 41
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 386 388 386 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 408 414 408 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 586 592 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 681 686 681 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mlh1 </italic>
###xml 716 718 716 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 696 701 <span type="species:ncbi:4932">yeast</span>
###xml 915 920 <span type="species:ncbi:9606">human</span>
###xml 1017 1025 <span type="species:ncbi:9606">patients</span>
The results of functional characterization of the hMLH1 variants are presented in Table 2. The amino acid alteration A92P did not alter MMR function, since the mutation rate was the same as observed in the wild-type parental MV400 strain. The 1.8-fold greater mutation rate in the strain expressing K618T variant, in comparison with the parental MV400 strain, was also not significant (P = 0.69). Six of the hMLH1 codon changes analyzed encode proteins which were observed in this study to support intermediate efficiencies of DNA MMR. The mutation rates measured in strains expressing hMLH1 variants S93G, T117M, I219V, K618R, Y646C and R659Q were significantly lower than in the mlh1 deficient yeast strain MV100 (P < 0.0001). Mutation rates of T117M, Y646C and R659Q were also clearly (P < 0,0001) greater (12.3-, 15.8- and 7.9-fold, respectively) than those obtained in the strain MV400 co-expressing wild-type human orthologs. A frameshift mutation 1955 del 1 bp, an experimental control never reported in HNPCC-patients, exhibited complete loss of MMR activity as expected. The alteration conferred a 82.7-fold higher mutation rate, than exhibited by the wild-type parental MV400 strain.
###end p 41
###begin p 42
###xml 53 61 53 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 61 66 <span type="species:ncbi:4932">yeast</span>
Functional characterization of hMLH1 variants in the in vivo yeast-based system
###end p 42
###begin p 43
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 68 70 68 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
aThis variant is functionally indistinguishable from the wild-type (P > 0.05).
###end p 43
###begin p 44
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bFunctional significance of the variant did not correlate with available clinical data.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 570 582 570 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S cerevisiae</italic>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 730 739 730 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 831 832 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 838 846 838 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 906 907 906 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 969 977 969 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1163 1165 1163 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1305 1306 1305 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1423 1428 1423 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 1434 1436 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1500 1508 1500 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1557 1562 1557 1562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 1572 1577 1572 1577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMS2 </italic>
###xml 1957 1959 1957 1959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 282 287 <span type="species:ncbi:4932">yeast</span>
###xml 507 512 <span type="species:ncbi:4932">yeast</span>
###xml 564 569 <span type="species:ncbi:4932">yeast</span>
###xml 977 982 <span type="species:ncbi:4932">yeast</span>
###xml 1055 1061 <span type="species:ncbi:9606">humans</span>
###xml 1066 1071 <span type="species:ncbi:4932">yeast</span>
###xml 1140 1145 <span type="species:ncbi:9606">human</span>
###xml 1150 1155 <span type="species:ncbi:4932">yeast</span>
###xml 1488 1493 <span type="species:ncbi:4932">yeast</span>
###xml 1551 1556 <span type="species:ncbi:9606">human</span>
###xml 1566 1571 <span type="species:ncbi:9606">human</span>
###xml 1632 1637 <span type="species:ncbi:9606">human</span>
###xml 1679 1684 <span type="species:ncbi:4932">yeast</span>
###xml 1846 1852 <span type="species:ncbi:4932">yeasts</span>
Hundreds of hMLH1 alterations have been found in HNPCC patients and for many, especially those leading to amino acid substitutions, the pathogenicity is still difficult to interpret. These non-truncating mutations should be functionally characterized. For this purpose, a number of yeast-based assays evaluating the functional significance of MMR variants have been developed, based on the fact that MMR has been conserved throughout eukaryotic evolution. Because of conservation of cellular functions from yeast to mammals and the ease of genetic manipulation in yeast S cerevisiae, this unicellular organism has been used before for assessing patogenicity of other cancer-related genes (eg. BRCA1 and p53) [27,28]. Besides many in vitro functional assays that require separate characterization of multiple functional properties [9,12], in vivo tests have been developed which appear to be more reliable [7,10,11,13]. However, it is important to note that, with known in vivo yeast assays, only mutations occurring in evolutionarily conserved regions in humans and yeast could be functionally analyzed, due to the lack of homology between human and yeast genes [14,15]. Moreover, clinical data associated with the disease usually lack to correlate with functional analysis data (for references see Table 1). Considering the fact that the efficiency of mismatch repair is highly affected by the degree of expression of the MLH1 gene [15] (variable in an episomal way), we have proposed a yeast-based in vivo system co-expressing chromosome-integrated human MLH1 and human PMS2 genes. With this intervention, the expressions of both human genes were controlled by the orthologous yeast promoters. Besides that, the expression of gene in chromosome seems to be region-depended. Higher-expressed and lower-expressed regions have been reported along yeasts' chromosome III. Moreover, the stability of foreign gene in chromosome is better than that in plasmids [29].
###end p 46
###begin p 47
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 260 264 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mlh1</italic>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 395 401 395 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 477 482 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMS1 </italic>
###xml 487 493 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2 </italic>
###xml 676 677 676 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 161 166 <span type="species:ncbi:9606">human</span>
###xml 195 200 <span type="species:ncbi:4932">yeast</span>
###xml 206 211 <span type="species:ncbi:9606">human</span>
###xml 275 280 <span type="species:ncbi:4932">yeast</span>
###xml 471 476 <span type="species:ncbi:4932">yeast</span>
###xml 558 563 <span type="species:ncbi:4932">yeast</span>
###xml 599 604 <span type="species:ncbi:9606">human</span>
The MLH1 protein contains an amino-terminal ATPase domain and a carboxy-terminal domain. According to Ellison's conclusion [10] and to our unpublished data, the human ATP domain is functional in yeast. The human ortholog alone does not restore MMR activity in mlh1-deficient yeast cells when expressed episomally [13]. The same appeared to be true with the chromosomal integration of the entire hMLH1 performed in our study (Figure 2). However, additional replacement of yeast PMS1 with hPMS2 (which encodes a heterodimeric partner of hMLH1) directly on the yeast chromosome, in a strain expressing human MLH1 protein, resulted in complete restoration of MMR function (Figure 2).
###end p 47
###begin p 48
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMS2 </italic>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 358 363 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 701 702 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 146 151 <span type="species:ncbi:9606">human</span>
Co-expression of human MLH1 and PMS2 proved to be effective for evaluating the pathogenicity of alterations found throughout the coding region of human MLH1 gene. Nine different hMLH1 alterations were shown to bring about from little or no effect on protein function to complete loss of MMR activity (Table 2). Before interpreting the pathogenicity of these MLH1 alterations, the appropriate tolerance level for functional proficiency had to be established. For this reason, hMLH1 missense alteration I219V was included in the assay as the functional control. This hMLH1 modification is a known harmless polymorphism consistently reported to have no functional effect on MLH1 (for reference see Table 1). In our test system the variant exhibited a significantly greater mutation rate than the wild-type. We therefore propose that 3-fold increase in mutation rate over the wild-type is the reasonable threshold between harmless variants on one side, and the variants with reduced MMR activity that may contribute to cancer susceptibility on the other side of a threshold. The proposed treshold might change, as the pathogenicities of more variants with proven phenotypes are assessed with the described approach.
###end p 48
###begin p 49
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 656 657 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 896 898 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1177 1178 1177 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 789 796 <span type="species:ncbi:9606">patient</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
Accordingly, the amino acid changes A92P, S93G, K618R and K618T were classified as non-pathogenic variations (Table 2). S93G is associated with a late age of onset, but has been reported in biochemical studies to have no functional effect on MLH1. The latter was confirmed in our study. The alteration K618T has been functionally characterized with various biological tools, with controversial results as to its pathogenicity. Our results correlate with clinical studies, in which K618T was reported not to co-segregate with the disease and in which affected carriers showed microsatellite stability and normal immunohistochemical staining of MLH1. (Table 1). Modifications A92P and K618R were functionally characterized for the first time. The novel amino acid change A92P was found in a patient with gastric carcinoma, and reported as probably pathogenic from its predicted structural changes [30]. The K618R modification was identified in colorectal cancer patients, however the clinical data are rather incomplete. The results of our assay suggest that these two modifications may not be causally associated with the observed clinical phenotype in mutation carriers (Table 1). Nevertheless, A92P, S93G, K618R and K618T must not be considered as absolutely non-pathogenic. Some alterations, despite being functionally proficient, exhibited reduction of protein efficiency that was significant compared to the wild-type, and mutation carriers may still, with low penetrance, express a particular phenotype. Therefore functional data have to be considered carefully alondside clinical studies that need to be undertaken with much more caution.
###end p 49
###begin p 50
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 646 647 646 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 765 766 765 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 930 939 930 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 957 958 957 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
According to our assay, a further four alterations, including the functional control - a frameshift mutation 1995 del 1 bp - should be considered as pathogenic variants. As assumed before, the missense mutations did not completely destroy protein function and are thus expected to result in incomplete clinical penetrance [31]. In this study, we confirmed previous reports showing that the T117M variant may be associated with pathogenicity in HNPCC (Table 1). Functional characterization of another two variants (Y646C and R659Q) was, however, not consistent with other functional studies, in which they were identified as non-pathogenic (Table 2). However, carriers of these variants developed cancer at early-middle age and showed HNPCC clinical features (Table 1). The discrepancy between our assay and previous functional studies can be explained by the conclusion that subtle functional alterations may not be revealed with in vitro biological tools [9]. In our study, complete elimination of MMR function was only established with the frameshift mutation 1995 del 1 bp.
###end p 50
###begin title 51
Conclusion
###end title 51
###begin p 52
###xml 30 39 30 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2 </italic>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 420 426 420 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 452 460 452 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 591 596 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 117 122 <span type="species:ncbi:4932">yeast</span>
###xml 440 445 <span type="species:ncbi:4932">yeast</span>
We have shown, in contrast to in vitro studies, that co-employing the chromosome-integrated hMLH1 and hPMS2 genes in yeast not only enabled pathogenic MLH1 variants to be discriminated from polymorphisms that have no effect on MMR function, but also enabled variants resulting in reduced MMR activity to be identified and functionally classified. Moreover, the results correlated with clinical data in five out of seven hMLH1 variants. Our yeast-based in vivo system may thus be used for functional characterization of variants with incomplete clinical data, since precise quantification of MLH1 variants is critical for effective early diagnosis and prognosis, as well as for genetic counselling of affected individuals.
###end p 52
###begin title 53
Competing interests
###end title 53
###begin p 54
The authors declare that they have no competing interests.
###end p 54
###begin title 55
Authors' contributions
###end title 55
###begin p 56
MV participated in the design of the study, performed the statistical analysis and drafted the manuscript. MV and NZ carried out the experiments. AC and PH participated in the design of the study. RK coordinated the study and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 56
###begin title 57
Pre-publication history
###end title 57
###begin p 58
The pre-publication history for this paper can be accessed here:
###end p 58
###begin p 59

###end p 59
###begin title 60
Acknowledgements
###end title 60
###begin p 61
We thank Drs. Francesca Storici and Thomas D. Petes for kindly providing pCORE and pSH91 plasmids, and Drs. Bert Vogelstein and Kenneth W. Kinzler for providing pSG-PMS2-wt plasmid. We thank Jelka Lenarcic for excellent technical assistance. The authors are grateful to Professor Bill Milne and Professor Roger Pain for critical reading of the manuscript. This work was supported by grant P1-0104 from ARRS and a JI grant to author MV.
###end p 61
###begin article-title 62
Cancer genes and the pathways they control
###end article-title 62
###begin article-title 63
Multiple mutations and cancer
###end article-title 63
###begin article-title 64
Functional analysis of MLH1 mutations linked to hereditary nonpolyposis colon cancer
###end article-title 64
###begin article-title 65
Mismatch repair defects in cancer
###end article-title 65
###begin article-title 66
MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability
###end article-title 66
###begin article-title 67
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features
###end article-title 67
###begin article-title 68
###xml 2 7 <span type="species:ncbi:4932">yeast</span>
A yeast two-hybrid assay provides a simple way to evaluate the vast majority of hMLH1 germ-line mutations
###end article-title 68
###begin article-title 69
Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX
###end article-title 69
###begin article-title 70
Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1
###end article-title 70
###begin article-title 71
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 78 83 <span type="species:ncbi:4932">yeast</span>
###xml 101 125 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Functional analysis of human MLH1 and MSH2 missense variants and hybrid human-yeast MLH1 proteins in Saccharomyces cerevisiae
###end article-title 71
###begin article-title 72
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 49 54 <span type="species:ncbi:4932">yeast</span>
Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays
###end article-title 72
###begin article-title 73
###xml 74 79 <span type="species:ncbi:9606">human</span>
Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system
###end article-title 73
###begin article-title 74
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 47 71 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Functional analysis of human MLH1 mutations in Saccharomyces cerevisiae
###end article-title 74
###begin article-title 75
Mutator phenotypes of common polymorphisms and missense mutations in MSH2
###end article-title 75
###begin article-title 76
###xml 63 68 <span type="species:ncbi:4932">yeast</span>
Inactivation of DNA mismatch repair by increased expression of yeast MLH1
###end article-title 76
###begin article-title 77
Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants
###end article-title 77
###begin article-title 78
###xml 28 33 <span type="species:ncbi:4932">yeast</span>
One-step gene disruption in yeast
###end article-title 78
###begin article-title 79
In vivo site-directed mutagenesis using oligonucleotides
###end article-title 79
###begin article-title 80
###xml 54 59 <span type="species:ncbi:4932">yeast</span>
Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair
###end article-title 80
###begin article-title 81
###xml 52 57 <span type="species:ncbi:9606">human</span>
Mismatch repair deficiency in phenotypically normal human cells
###end article-title 81
###begin article-title 82
###xml 4 9 <span type="species:ncbi:4932">yeast</span>
###xml 10 26 <span type="species:ncbi:562">Escherichia coli</span>
###xml 81 86 <span type="species:ncbi:4932">yeast</span>
New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites
###end article-title 82
###begin article-title 83
###xml 72 96 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
New heterologous modules for classical or PCR-based gene disruptions in Saccharomyces cerevisiae
###end article-title 83
###begin article-title 84
###xml 68 92 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Functional genetic tests of DNA mismatch repair protein activity in Saccharomyces cerevisiae
###end article-title 84
###begin article-title 85
###xml 18 23 <span type="species:ncbi:4932">yeast</span>
Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method
###end article-title 85
###begin article-title 86
The contribution of the number of mutants in bacterial populations
###end article-title 86
###begin article-title 87
###xml 51 56 <span type="species:ncbi:4932">yeast</span>
Regulation of mitotic homeologous recombination in yeast. Functions of mismatch repair and nucleotide excision repair genes
###end article-title 87
###begin article-title 88
###xml 2 7 <span type="species:ncbi:4932">yeast</span>
###xml 44 49 <span type="species:ncbi:9606">human</span>
A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance
###end article-title 88
###begin article-title 89
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 78 83 <span type="species:ncbi:4932">yeast</span>
Screening patients for heterozygous p53 mutations using a functional assay in yeast
###end article-title 89
###begin article-title 90
###xml 63 68 <span type="species:ncbi:4932">yeast</span>
###xml 69 93 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Region specificity of chromosome III on gene expression in the yeast Saccharomyces cerevisiae
###end article-title 90
###begin article-title 91
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Mutations in the hMLH1 gene in Slovenian patients with gastric carcinoma
###end article-title 91
###begin article-title 92
Germline HNPCC gene variants have little influence on the risk for sporadic colorectal cancer
###end article-title 92
###begin article-title 93
Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors
###end article-title 93
###begin article-title 94
Hereditary nonpolyposis coloretal cancer: identification of novel germline mutations in two kindreds not fulfulling the Amsterdam criteria. Mutations in brief no. 203. Online
###end article-title 94
###begin article-title 95
Evaluation of rapid microsatellite analysis of paraffin-embedded specimens in screening for hereditary nonpolyposis colorectal cancer
###end article-title 95
###begin article-title 96
Detection of new mutations in six out of 10 Swiss HNPCC families by genomic sequencing of the hMSH2 and hMLH1 genes
###end article-title 96
###begin article-title 97
Impact of microsatellite testing and mismatch repair protein expression on the clinical interpretation of genetic testing in hereditary non-polyposis colorectal cancer
###end article-title 97
###begin article-title 98
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients
###end article-title 98
###begin article-title 99
Extensive molecular screening for hereditary non-polyposis colorectal cancer
###end article-title 99
###begin article-title 100
Immunohistochemical detection of the hMLH1 and hMSH2 proteins in hereditary non-polyposis colon cancer and sporadic colon cancer
###end article-title 100
###begin article-title 101
Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation
###end article-title 101
###begin article-title 102
A novel mutation detection approach of hMLH1 and hMSH2 genes for screening of colorectal cancer
###end article-title 102
###begin article-title 103
###xml 23 28 <span type="species:ncbi:9606">human</span>
The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer
###end article-title 103
###begin article-title 104
Assessment of pathogenicity criteria for constitutional missense mutations of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2
###end article-title 104
###begin article-title 105
Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: implications for genetic testing
###end article-title 105
###begin article-title 106
hMLH1 and hMSH2 gene mutation in Brazilian families with suspected hereditary nonpolyposis colorectal cancer
###end article-title 106
###begin article-title 107
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression
###end article-title 107
###begin article-title 108
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation
###end article-title 108

